AX 201

Drug Profile

AX 201

Alternative Names: AX201

Latest Information Update: 30 Jul 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SYGNIS Bioscience GmbH
  • Class
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease; Stroke

Most Recent Events

  • 25 Jul 2012 Discontinued - Preclinical for Parkinson's disease in Germany (unspecified route)
  • 25 Jul 2012 Discontinued - Preclinical for Stroke in Germany (unspecified route)
  • 12 Dec 2006 Preclinical development of AX 201 is still ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top